Browsing by Author "Harris-Brown, Tiffany"
Now showing items 1-2 of 2
-
Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance a randomized clinical trial
Harris, Patrick N. A.; Tambyah, Paul Anatharajah; Lye, David Chien; Mo Yinli; Lee, Tau Hong; Yılmaz, Mesut; Alenazi, Tamer H.; Arabi, Yaseen; Falcone, Marco; Bassetti, Matteo; Righi, Elda; Rogers, Benjamin A.; Kanj, Souha; Bhally, Hasan; Iredell, Jon; Mendelson, Marc; Boyles, Tom H.; Looke, David; Miyakis, Spiros; Walls, Genevieve; Al Khamis, Mohammed; Zikri, Ahmed; Crowe, Amy; Ingram, Paul; Daneman, Nick; Griffin, Paul; Athan, Eugene; Lorenc, Penelope; Baker, Peter; Roberts, Leah; Beatson, Scott A.; Peleg, Anton Y.; Harris-Brown, Tiffany; Paterson, David L. (American Medical Association, 2018)IMPORTANCE Extended-spectrum beta-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually ... -
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase-producing enterobacter spp, citrobacter freundii, morganella morganii, providencia spp, or serratia marcescens: A pilot multicenter randomized controlled trial (MERINO-2)
Stewart, Adam G.; Paterson, David L.; Young, Barnaby; Lye, David C.; Davis, Joshua S.; Schneider, Kellie; Yılmaz, Mesut; Dinleyici, Rümeysa; Runnegar, Naomi; Henderson, Andrew; Archuleta, Sophia; Kalimuddin, Shirin; Forde, Brian M.; Chatfield, Mark D.; Bauer, Michelle J.; Lipman, Jeffrey; Harris-Brown, Tiffany; Harris, Patrick N. A. (Oxford University Press, 2021)Background: Carbapenems are recommended treatment for serious infections caused by AmpC-producing gram-negative bacteria but can select for carbapenem resistance. Piperacillin-tazobactam may be a suitable alternative. ...
